AU5551190A - Method of inhibiting induction of latent or chronic viral infections - Google Patents
Method of inhibiting induction of latent or chronic viral infectionsInfo
- Publication number
- AU5551190A AU5551190A AU55511/90A AU5551190A AU5551190A AU 5551190 A AU5551190 A AU 5551190A AU 55511/90 A AU55511/90 A AU 55511/90A AU 5551190 A AU5551190 A AU 5551190A AU 5551190 A AU5551190 A AU 5551190A
- Authority
- AU
- Australia
- Prior art keywords
- oligomer
- virus
- nucleosides
- viral
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34150889A | 1989-04-21 | 1989-04-21 | |
US341508 | 1989-04-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64651/94A Division AU6465194A (en) | 1989-04-21 | 1994-06-09 | Method of inhibiting induction of latent or chronic viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5551190A true AU5551190A (en) | 1990-11-16 |
Family
ID=23337878
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU55511/90A Abandoned AU5551190A (en) | 1989-04-21 | 1990-04-19 | Method of inhibiting induction of latent or chronic viral infections |
AU64651/94A Abandoned AU6465194A (en) | 1989-04-21 | 1994-06-09 | Method of inhibiting induction of latent or chronic viral infections |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64651/94A Abandoned AU6465194A (en) | 1989-04-21 | 1994-06-09 | Method of inhibiting induction of latent or chronic viral infections |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0469080A4 (xx) |
JP (1) | JPH04505615A (xx) |
KR (1) | KR920700654A (xx) |
AU (2) | AU5551190A (xx) |
CA (1) | CA2014990A1 (xx) |
WO (1) | WO1990012578A1 (xx) |
ZA (1) | ZA902912B (xx) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU636573B2 (en) * | 1988-02-26 | 1993-05-06 | Worcester Foundation For Biomedical Research, Inc. | Inhibition of htlv-iii by exogenous oligonucleotides |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2105595A1 (en) * | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
GB2392157B (en) | 2001-05-16 | 2005-12-21 | Micrologix Biotech Inc | Nucleic acid-based compounds and methods of use thereof |
RU2207876C1 (ru) * | 2001-11-08 | 2003-07-10 | Ткаченко Виталий Васильевич | Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757055A (en) * | 1980-11-12 | 1988-07-12 | The Johns Hopkins University | Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells |
US4511713A (en) * | 1980-11-12 | 1985-04-16 | The Johns Hopkins University | Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells |
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
-
1990
- 1990-04-18 ZA ZA902912A patent/ZA902912B/xx unknown
- 1990-04-19 AU AU55511/90A patent/AU5551190A/en not_active Abandoned
- 1990-04-19 WO PCT/US1990/002011 patent/WO1990012578A1/en not_active Application Discontinuation
- 1990-04-19 JP JP2506795A patent/JPH04505615A/ja active Pending
- 1990-04-19 EP EP19900907966 patent/EP0469080A4/en not_active Withdrawn
- 1990-04-19 KR KR1019910701402A patent/KR920700654A/ko not_active Application Discontinuation
- 1990-04-20 CA CA002014990A patent/CA2014990A1/en not_active Abandoned
-
1994
- 1994-06-09 AU AU64651/94A patent/AU6465194A/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU636573B2 (en) * | 1988-02-26 | 1993-05-06 | Worcester Foundation For Biomedical Research, Inc. | Inhibition of htlv-iii by exogenous oligonucleotides |
Also Published As
Publication number | Publication date |
---|---|
CA2014990A1 (en) | 1990-10-21 |
AU6465194A (en) | 1994-10-06 |
KR920700654A (ko) | 1992-08-10 |
WO1990012578A1 (en) | 1990-11-01 |
EP0469080A4 (en) | 1992-04-29 |
EP0469080A1 (en) | 1992-02-05 |
ZA902912B (en) | 1991-01-30 |
JPH04505615A (ja) | 1992-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Montano et al. | Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes | |
EP0412964B1 (en) | Inhibition of htlv-iii by exogenous oligonucleotides | |
Rosen et al. | Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III | |
Okamoto et al. | Demonstration of virus-specific transcriptional activator (s) in cells infected with HTLV-III by an in vitro cell-free system | |
Woffendin et al. | Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. | |
Harrich et al. | Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat | |
Paca-Uccaralertkun et al. | In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax | |
US5166195A (en) | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides | |
Brighty et al. | A cis-acting repressive sequence that overlaps the Rev-responsive element of human immunodeficiency virus type 1 regulates nuclear retention of env mRNAs independently of known splice signals. | |
Estable et al. | Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity | |
Michael et al. | Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities | |
EP0402402B1 (en) | Inhibition of htlv-iii by exogenous oligonucleotides | |
US5821046A (en) | RNA oligonucleotides that bind HIV tat protein | |
Sharmeen et al. | Tat-dependent adenosine-to-inosine modification of wild-type transactivation response RNA. | |
Belshan et al. | Biological characterization of Rev variation in equine infectious anemia virus | |
Sakuragi et al. | Dissociation of genome dimerization from packaging functions and virion maturation of human immunodeficiency virus type 1 | |
Cereseto et al. | Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines | |
Bohan et al. | Sodium butyrate activates human immunodeficiency virus long terminal repeat—directed expression | |
Gutekunst et al. | Transcription of the HIV-1 LTR is regulated by the density of DNA CpG methylation | |
Vigne et al. | Transcription of visna virus during its lytic cycle: evidence for a sequential early and late gene expression | |
AU5551190A (en) | Method of inhibiting induction of latent or chronic viral infections | |
US5622854A (en) | Method and reagent for inhibiting T-cell leukemia virus replication | |
WO1994029479A9 (en) | Oligonucleotides which inhibit hiv protease function | |
WO1994029479A1 (en) | Oligonucleotides which inhibit hiv protease function | |
WO1992020813A1 (en) | Assays for factors affecting circularization of dna, assays for factors affecting dna integration, factors, and uses thereof |